Shire just nabbed FDA panel backing for prucalopride, aiming to challenge Allergan and Synergy in the chronic constipation market.
As a big ESMO 2018 kicks off, here are the studies we're most excited to see.
On Thursday, Merck’s Keytruda hit the scene with kidney cancer combination data that could snag it a new use months earlier than anticipated.
The FDA OPDP slapped a warning letter on Mannkind for failing to mention Afrezza's risks.
Merck is joining the chief digital officer parade, hiring Jim Scholefield from Nike to head up IT and digital strategy—not to mention cybersecurity.
GlaxoSmithKline's new Theraflu rollout? Single-use plastic pods that fit into Keurig coffee makers, hitting shelves this month supported by an ad effort.
FCB Health is looking to humanize data, formalizing that vision into its own distinct next generation big data agency named Solve(d).
Pharma might have thought it could fend off the Trump administration's bid to get drug prices into consumer advertising, but it was wrong.
Roche is teeing up a new use for its breast cancer drug Kadcyla, hoping to gin up sales as Herceptin biosimilars hurtle toward the U.S. market.
With three quarters of pharma TV ad spending down and one to go, national media buys are tracking ahead of 2017, with brands doling out $2.81 billion.
